JP2014515367A - 不活性化デング熱ウイルスワクチン - Google Patents

不活性化デング熱ウイルスワクチン Download PDF

Info

Publication number
JP2014515367A
JP2014515367A JP2014511908A JP2014511908A JP2014515367A JP 2014515367 A JP2014515367 A JP 2014515367A JP 2014511908 A JP2014511908 A JP 2014511908A JP 2014511908 A JP2014511908 A JP 2014511908A JP 2014515367 A JP2014515367 A JP 2014515367A
Authority
JP
Japan
Prior art keywords
immunogenic composition
dengue virus
inactivated dengue
preparation
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014511908A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014515367A5 (cg-RX-API-DMAC7.html
Inventor
ヘンドリックス，ヴェロニク
ビュッシー，オリヴィエ ル
ルモアーヌ，ドミニク，イングリッド
マトー，フレデリク
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2014515367A publication Critical patent/JP2014515367A/ja
Publication of JP2014515367A5 publication Critical patent/JP2014515367A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2014511908A 2011-05-26 2012-05-25 不活性化デング熱ウイルスワクチン Pending JP2014515367A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161490205P 2011-05-26 2011-05-26
US61/490,205 2011-05-26
US201161570966P 2011-12-15 2011-12-15
US61/570,966 2011-12-15
PCT/EP2012/059879 WO2012160199A1 (en) 2011-05-26 2012-05-25 Inactivated dengue virus vaccine

Publications (2)

Publication Number Publication Date
JP2014515367A true JP2014515367A (ja) 2014-06-30
JP2014515367A5 JP2014515367A5 (cg-RX-API-DMAC7.html) 2015-06-11

Family

ID=46148894

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014511908A Pending JP2014515367A (ja) 2011-05-26 2012-05-25 不活性化デング熱ウイルスワクチン

Country Status (16)

Country Link
US (1) US20140112953A1 (cg-RX-API-DMAC7.html)
EP (1) EP2714076A1 (cg-RX-API-DMAC7.html)
JP (1) JP2014515367A (cg-RX-API-DMAC7.html)
KR (1) KR20140033171A (cg-RX-API-DMAC7.html)
CN (2) CN107050445A (cg-RX-API-DMAC7.html)
AU (2) AU2012260807B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013030236A2 (cg-RX-API-DMAC7.html)
CA (1) CA2837145A1 (cg-RX-API-DMAC7.html)
CO (1) CO6811814A2 (cg-RX-API-DMAC7.html)
EA (1) EA201391515A1 (cg-RX-API-DMAC7.html)
IL (1) IL229307A0 (cg-RX-API-DMAC7.html)
MX (1) MX349119B (cg-RX-API-DMAC7.html)
PE (1) PE20140646A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013502442A1 (cg-RX-API-DMAC7.html)
SG (1) SG194950A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012160199A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023508852A (ja) * 2019-12-11 2023-03-06 エヌイーワン インコーポレイテッド 個別化腫瘍ワクチンおよびがん免疫療法のためのその使用
JP2023516009A (ja) * 2020-02-27 2023-04-17 タケダ ワクチン，インコーポレイテッド ウイルス調製物から宿主細胞ｄｎａを取り除く方法
US12491229B2 (en) 2014-11-18 2025-12-09 Shionogi & Co., Ltd. Stabilized peptide composition

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016145149A1 (en) * 2015-03-11 2016-09-15 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Combination purified inactivated vaccine for flaviviruses
EP3316897A4 (en) 2015-07-02 2019-03-13 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS
US10765727B2 (en) 2015-09-26 2020-09-08 PrimeVax Immuno-Oncology, Inc. Compositions and methods for producing dendritic cells
GB201522068D0 (en) * 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Dried composition
BE1024160A9 (fr) * 2015-12-22 2017-12-06 Glaxosmithkline Biologicals Sa Formulation immunogène
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
WO2018093907A1 (en) 2016-11-16 2018-05-24 PrimeVax Immuno-Oncology, Inc. Combination immunotherapies for treatment of cancer
WO2018129202A1 (en) * 2017-01-04 2018-07-12 PrimeVax Immuno-Oncology, Inc. Compositions and methods for therapy with dengue virus
CN107140625A (zh) * 2017-06-14 2017-09-08 中国海洋大学 一种利用植物油制备石墨烯薄膜的方法
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
CN111526885A (zh) 2017-11-03 2020-08-11 武田疫苗股份有限公司 寨卡疫苗和免疫原性组合物及其使用方法
CA3084605A1 (en) 2017-11-30 2019-06-06 Takeda Vaccines, Inc. Method for inactivating zika virus and related methods
CN111447947B (zh) 2017-12-07 2024-01-12 默沙东有限责任公司 登革病毒疫苗组合物的制剂
CN112546213A (zh) * 2020-12-31 2021-03-26 中国医学科学院医学生物学研究所 一种制备新型冠状病毒疫苗的方法及针对其有效性的评价方法
CN113750228B (zh) * 2021-09-25 2024-02-20 大连理工大学 一种冷冻保护剂在铝佐剂中的应用
CN115531529A (zh) * 2022-09-16 2022-12-30 大连理工大学 一种冻干保护剂在含铝佐剂中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254873B1 (en) * 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
JP2006517233A (ja) * 2003-02-10 2006-07-20 エラン ファーマシューティカルズ，インコーポレイテッド 免疫グロブリン製剤およびその調製の方法
JP2008500399A (ja) * 2004-05-21 2008-01-10 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 呼吸器系病原体ワクチンのためのアルファウイルスベクター
WO2010035119A2 (en) * 2008-09-29 2010-04-01 Cadila Pharmaceuticals Ltd. Vaccine adjuvants
JP2010523127A (ja) * 2007-04-06 2010-07-15 インビラジェン， インコーポレイテッド 弱毒生ウイルスのための方法および組成物
WO2010094663A1 (en) * 2009-02-17 2010-08-26 Glaxosmithkline Biologicals S.A. Inactivated dengue virus vaccine with aluminium-free adjuvant

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03002890A (es) * 2000-10-02 2004-12-03 Glaxosmithkline Biolog Sa Preparacion de virus con envolvente dividido.
KR101357685B1 (ko) * 2005-11-21 2014-02-06 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 재조합 바이러스용 안정화 제형
US9005633B2 (en) * 2009-07-17 2015-04-14 The United States Of America As Represented By The Secretary Of The Navy. Psoralen-inactivated viral vaccine and method of preparation
US8557253B2 (en) * 2009-10-07 2013-10-15 Sanofi Pasteur Sa Stabilizing excipient for inactivated whole virus vaccine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254873B1 (en) * 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
JP2006517233A (ja) * 2003-02-10 2006-07-20 エラン ファーマシューティカルズ，インコーポレイテッド 免疫グロブリン製剤およびその調製の方法
JP2008500399A (ja) * 2004-05-21 2008-01-10 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 呼吸器系病原体ワクチンのためのアルファウイルスベクター
JP2010523127A (ja) * 2007-04-06 2010-07-15 インビラジェン， インコーポレイテッド 弱毒生ウイルスのための方法および組成物
WO2010035119A2 (en) * 2008-09-29 2010-04-01 Cadila Pharmaceuticals Ltd. Vaccine adjuvants
WO2010094663A1 (en) * 2009-02-17 2010-08-26 Glaxosmithkline Biologicals S.A. Inactivated dengue virus vaccine with aluminium-free adjuvant

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NEWMAN M J: "USE OF NONIONIC BLOCK COPOLYMERS IN VACCINES AND THERAPEUTICS", CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, vol. V15 N2, JPN5014007376, 1 January 1998 (1998-01-01), US, pages 89 - 142, ISSN: 0003253766 *
VACCINE, 1997, VOL.15, NO.14, P.1494-1502, JPN6016041742, ISSN: 0003429715 *
VACCINE, 1999, VOL.17, P.1312-1320, JPN6016041745, ISSN: 0003429716 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12491229B2 (en) 2014-11-18 2025-12-09 Shionogi & Co., Ltd. Stabilized peptide composition
JP2023508852A (ja) * 2019-12-11 2023-03-06 エヌイーワン インコーポレイテッド 個別化腫瘍ワクチンおよびがん免疫療法のためのその使用
JP2023516009A (ja) * 2020-02-27 2023-04-17 タケダ ワクチン，インコーポレイテッド ウイルス調製物から宿主細胞ｄｎａを取り除く方法
JP7648642B2 (ja) 2020-02-27 2025-03-18 タケダ ワクチン，インコーポレイテッド ウイルス調製物から宿主細胞ｄｎａを取り除く方法

Also Published As

Publication number Publication date
CA2837145A1 (en) 2012-11-29
AU2016210743A1 (en) 2016-08-25
EA201391515A1 (ru) 2014-05-30
BR112013030236A2 (pt) 2016-12-06
CO6811814A2 (es) 2013-12-16
CN103619349A (zh) 2014-03-05
KR20140033171A (ko) 2014-03-17
US20140112953A1 (en) 2014-04-24
PH12013502442A1 (en) 2018-03-21
IL229307A0 (en) 2014-01-30
WO2012160199A1 (en) 2012-11-29
MX349119B (es) 2017-07-12
CN107050445A (zh) 2017-08-18
AU2012260807B2 (en) 2016-05-12
EP2714076A1 (en) 2014-04-09
MX2013013862A (es) 2014-01-23
PE20140646A1 (es) 2014-05-29
SG194950A1 (en) 2013-12-30

Similar Documents

Publication Publication Date Title
AU2012260807B2 (en) Inactivated Dengue virus vaccine
AU2012260807A1 (en) Inactivated Dengue virus vaccine
JP2021138745A (ja) ワクチン組成物
US9265821B2 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
CN104755100B (zh) 用于在婴儿中引发针对rsv和百日咳博德特氏菌的免疫应答的方法
CN107406856A (zh) 手、足及口疫苗及其制备及使用方法
EP3474891B1 (en) Vaccine compositions comprising an attenuated mutant zika virus
US20160193322A1 (en) Combination immunogenic compositions
ES2924914T3 (es) Vacuna contra rinovirus humano
WO2014024026A1 (en) Method for eliciting in infants an immune response against rsv and b. pertussis
AU2016222377B2 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
AU2014200047B2 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170314